Shiloh
Editor, Senior Moderator
Source: http://www.eurekalert.org/pub_releases/2011-10/bumc-srm101811.php
Public release date: 19-Oct-2011
Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Scientists report major advance in the treatment of Hendra virus
(Boston) - A collaborative research team from Boston University School of Medicine (BUSM), the Uniformed Services University of the Health Sciences (USU), the University of Texas Medical Branch (UTMB) and Galveston National Laboratory (GNL), the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Rocky Mountain Laboratories (RML), and the National Cancer Institute (NCI), reports a breakthrough in the development of an effective therapy against a deadly virus, Hendra virus. The results of their research will appear in Science Translational Medicine and the full study will be available following the release of the embargo at 2 p.m. October 19, 2011.
Hendra virus and the closely related Nipah virus are emerging viruses capable of causing severe illness and death in humans and a variety of domestic animals. As both viruses have an animal reservoir in nature, eradication is not possible and outbreaks of severe disease will continue to occur.
In experiments carried out at the RML in Hamilton, MT, where there is a high-level safety and security facility for working with live Hendra virus, the team of researchers demonstrated that giving an anti-virus human monoclonal antibody therapy after exposure to Hendra virus protected animals from lethal disease.
"These findings are really quite promising and appear to offer a real potential treatment for Hendra virus infection in people," said Christopher C. Broder, PhD, professor of microbiology at USU and study corresponding author...
*******************************
Source: http://www.eurekalert.org/pub_releases/2011-10/hmjf-srm101911.php
Public release date: 19-Oct-2011
Contact: JoAnn Sperber
jsperber@hjf.org
240-694-2163
Henry M. Jackson Foundation for the Advancement of Military Medicine
Scientists report major advance in human antibody therapy against deadly Hendra virus
Bethesda, MD—A team of Federal and university scientists reports a breakthrough in the development of an effective therapy against a deadly virus, Hendra virus. The results of their study, "A Neutralizing Human Monoclonal Antibody Protects African Green Monkeys from Hendra Virus Challenge," will appear in Science Translational Medicine online. The full study will be available following the release of the embargo at 2 p.m. Oct. 19, 2011.
The collaborative research team members are from the Uniformed Services University of the Health Sciences (USU), the University of Texas Medical Branch (UTMB) and Galveston National Laboratory (GNL), the National Institutes of Health (NIH's) National Institute of Allergy and Infectious Diseases (NIAID), Rocky Mountain Laboratories (RML), the National Emerging Infectious Diseases Laboratories Institute (NEIDL) at Boston University School of Medicine, and the National Cancer Institute (NCI), NIH. The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. manages the patent and played a central role in the transfer of the antibody and cell line to Queensland Health in Australia in 2010.
Hendra virus and the closely related Nipah virus are found in Pteropid fruit bats (flying foxes) and are emerging viruses capable of causing severe illness and death in a variety of domestic animals and humans.
In experiments carried out in African green monkeys at the RML in Hamilton, Montana, where there is a high-level safety and security facility for working with live Hendra virus, the team of researchers, under the direction of Heinz Feldmann, M.D., Ph.D., chief of the RML, Laboratory of Virology, demonstrated that giving an anti-virus human monoclonal antibody therapy after exposure to Hendra virus protected the animals from disease...
Public release date: 19-Oct-2011
Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Scientists report major advance in the treatment of Hendra virus
(Boston) - A collaborative research team from Boston University School of Medicine (BUSM), the Uniformed Services University of the Health Sciences (USU), the University of Texas Medical Branch (UTMB) and Galveston National Laboratory (GNL), the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Rocky Mountain Laboratories (RML), and the National Cancer Institute (NCI), reports a breakthrough in the development of an effective therapy against a deadly virus, Hendra virus. The results of their research will appear in Science Translational Medicine and the full study will be available following the release of the embargo at 2 p.m. October 19, 2011.
Hendra virus and the closely related Nipah virus are emerging viruses capable of causing severe illness and death in humans and a variety of domestic animals. As both viruses have an animal reservoir in nature, eradication is not possible and outbreaks of severe disease will continue to occur.
In experiments carried out at the RML in Hamilton, MT, where there is a high-level safety and security facility for working with live Hendra virus, the team of researchers demonstrated that giving an anti-virus human monoclonal antibody therapy after exposure to Hendra virus protected animals from lethal disease.
"These findings are really quite promising and appear to offer a real potential treatment for Hendra virus infection in people," said Christopher C. Broder, PhD, professor of microbiology at USU and study corresponding author...
*******************************
Source: http://www.eurekalert.org/pub_releases/2011-10/hmjf-srm101911.php
Public release date: 19-Oct-2011
Contact: JoAnn Sperber
jsperber@hjf.org
240-694-2163
Henry M. Jackson Foundation for the Advancement of Military Medicine
Scientists report major advance in human antibody therapy against deadly Hendra virus
Bethesda, MD—A team of Federal and university scientists reports a breakthrough in the development of an effective therapy against a deadly virus, Hendra virus. The results of their study, "A Neutralizing Human Monoclonal Antibody Protects African Green Monkeys from Hendra Virus Challenge," will appear in Science Translational Medicine online. The full study will be available following the release of the embargo at 2 p.m. Oct. 19, 2011.
The collaborative research team members are from the Uniformed Services University of the Health Sciences (USU), the University of Texas Medical Branch (UTMB) and Galveston National Laboratory (GNL), the National Institutes of Health (NIH's) National Institute of Allergy and Infectious Diseases (NIAID), Rocky Mountain Laboratories (RML), the National Emerging Infectious Diseases Laboratories Institute (NEIDL) at Boston University School of Medicine, and the National Cancer Institute (NCI), NIH. The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. manages the patent and played a central role in the transfer of the antibody and cell line to Queensland Health in Australia in 2010.
Hendra virus and the closely related Nipah virus are found in Pteropid fruit bats (flying foxes) and are emerging viruses capable of causing severe illness and death in a variety of domestic animals and humans.
In experiments carried out in African green monkeys at the RML in Hamilton, Montana, where there is a high-level safety and security facility for working with live Hendra virus, the team of researchers, under the direction of Heinz Feldmann, M.D., Ph.D., chief of the RML, Laboratory of Virology, demonstrated that giving an anti-virus human monoclonal antibody therapy after exposure to Hendra virus protected the animals from disease...
Last edited: